Worldwide Biotech

Browse past and current articles from this publication.

SANTHERA ENROLLS LAST PATIENT IN RHODOS STUDY.(Clinical report)
Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, has announced that recruitment has been completed for its six-month RHODOS st . . .

VICAL/TEVA SIGN SALES/MARKETING PACT FOR ALLOVECTIN IN ISRAEL.
Vical Incorporated (Nasdaq:VICL), San Diego, Calif. has announced an exclusive agreement with Abic Marketing Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., for sales and marketing of . . .

DEBIOPHARM/MERCURY SIGN LICENSE AGREEMENT FOR DEBIO 0930.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Mercury Therapeuti . . .

ORAMED AWARDED NIS 3.1 MILLION GRANT FROM ISRAEL.
Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a developer of oral delivery systems, has reported that its wholly owned Israeli subsidiary, Oramed Ltd., was awarded a government grant amounting to a . . .

COMPUGEN GETS POSITIVE EFFECTS FROM NOVEL PEPTIIDE FOR IBD.
Compugen Ltd. (NASDAQ:CGEN), Tel Aviv, Israel, has announced that CGEN-25007, a novel peptide antagonist of gp96 with potent anti-inflammatory activity, has shown positive therapeutic effects in an . . .

CDC RECOMMENDATION INCLUDES INTERCELL'S IXIARO VACCINATION.
Intercell AG (VSE: ICLL) has announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to update its previous recommendations . . .

02H/HYPOXIUM TO OFFER CELL-BASED ONCOLOGY ASSAYS.
O2h, Cambridge, England, has initiated a networked approach towards being a full service discovery services company at the forefront of drug discovery research. O2h has established a new biology lab . . .

SPAIN SELECTS NOVANAX'S VLP FOR FLU VACCINE.
Novavax, Inc. (NASDAQ: NVAX), Rockville, Md. has announced its initial agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: . . .

ELIGEN WITH GLP-1 AND PYY3-36 SUPPRESSES APPETITE.(Clinical report)
Emisphere Technologies, Inc. (NASDAQ: EMIS) has announced data from a clinical study designed to assess the effect of oral administration of two peptides, GLP-1 and PYY3-36, utilizing Emisphere's El . . .

AVITA GETS AU$2M FROM US MILITARY TO SPEED DEVICE APPROVAL.
Avita Medical Ltd (ASX: AVH) has been awarded US$1.45 million (AU$2 million) from the US Armed Forces Institute of Regenerative Medicine (AFIRM) to accelerate approval of the company's ReCell Autolo . . .

CYTOPIA PROGRAM REACHES MILESTONE AT CANCER THERAPEUTICS.
Cytopia Limited (ASX:CYT) has announced significant progress by Cancer Therapeutics CRC Pty Ltd (CTx) towards the identification of a pre-clinical drug candidate. This candidate is based on intellec . . .

PROTEO/MAYOLY SPINDLER FORM DRUG DEVELOPMENT PARTNERSHIP.
Protea Biosciences, Inc., Morgantown, W. Va., a leader in the development of new protein technology, has entered into a drug development partnership with LABORATOIRES MAYOLY SPINDLER (Mayoly), a Eur . . .

IRISH GASTROENTEROLOGY RESEARCHERS PIONEER IBS TREATMENTS.
Second only to the common cold as the leading source of workplace absenteeism in the Western world, Irritable Bowel Syndrome (IBS) is suffered by between 15 and 20 percent of all adolescents and adu . . .

BAYER/REGENERON EXTEND PROGRAM FOR VEGF TRAP-EYE.
Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) have announced that the companies are extending their global development program for VEGF Trap-Eye, an investigational agent for . . .

INIMEX BEGINS CLINICAL STUDY OF INNATE DEFENSE REGULATOR.
Inimex Pharmaceuticals, Vancouver, BC,, has announced that its novel Innate Defense Regulator (IDR) IMX942 was administered to human subjects for the first time on April 27, 2009. The healthy volunt . . .

CISBIO BIOASSAYS UNVEILS TAG-LITE FOR ASSAY DEVELOPMENT.
Cisbio Bioassays (http://www.htrf.com), member of IBA group and global developer of HTRF (Homogeneous Time-Resolved Fluorescence) technology and services used in assay development and drug screening . . .

SURVIVAL INPROVEMENT REPORTED IN SATRAPLATIN SPARC TRIAL.
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) has announced that data from the double-blind, randomized satraplatin Phase 3 trial, the SPARC trial (Satraplatin and Prednisone Against . . .

OREXO'S ASTRAL GETS TWO MORE EU MARKET APPROVALS.
Orexo (NASDAQ-OMX:ORX), has announced that Abstral has received Marketing Authorisation from the French and Spanish regulatory authorities for the treatment of breakthrough cancer pain. AbstralTM . . .

BAVARIAN NORDIC AGREES ON PATHAWAY FOR INVAMUNE LICENSURE.
Following the completion of the Phase II clinical development of IMVAMUNE(R), a third-generation smallpox vaccine, Bavarian Nordic has held an end of Phase II meeting with the FDA to discuss the Pha . . .

EPISTEM SIGNS R&D COLLABORATION WITH NOVARTIS.
Epistem Plc (LSE:EHP) the UK biotechnology and research services company has signed a research and development collaboration with Novartis to identify new drug targets and therapeutics across a vari . . .

JPT LAUNCHES "PEPTRACK" FOR T-CELL ASSAYS IN VACINE DEVELOPMENT.
JPT Peptide Technologies GmbH (JPT), Berlin, a wholly-owned subsidiary of Jerini AG (Frankfurt:JI4), has launched its new product line: PepTrack(tm). Designed for peptides in T-cell assays (ELISPOT, . . .

LEUCHEMIX PROVIDES UPDATE ON CANCER TRIAL.
CombiMatrix Corporation (Nasdaq:CBMX), Mukilteo, Wash., has announced that Leuchemix provided additional information regarding the initial clinical trial of its novel anticancer drug LC-1. The initi . . .

KAHR MEDICAL RAISES $500K FROM HADSIT BIO-HOLDINGS/ISRAEL MINISTRY.
KAHR Medical, Jerusalem, Israel, a Hadasit Bio-Holdings (HBL, TASE: HDST) portfolio company, has raised $500 thousand from HBL and the Office of the Chief Scientist of the Ministry of Industry, Trad . . .

BIOMS REPORTS ON PHASE II DIRUCOTIDE FOR MULTIPLE SCLEROSIS.
BioMS Medical Corp. (TSX: MS), Edmonton, Alberta, a leading developer in the treatment of multiple sclerosis (MS), today announced results from MINDSET-01, an exploratory phase II clinical trial eva . . .

AUSTRALIA GRANTS PRODUCT APPROVAL FOR ENCEPHLITIS VACINE.
Intercell AG (VSE: ICLL), Vienna, Austria, has announced that the Australian Therapeutic Goods Administration (TGA) granted product approval for the company's vaccine to prevent Japanese Encephaliti . . .

GENEREX ORAL INSULIN SPRAY APPROVED BY LEBANESE GOVERNMENT.
Generex Biotechnology Corporation (Nasdaq:GNBT), Worcester, Mass., the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has announced that Lebanon's Ministry of . . .

INTERCELL OUTLICENSES GROUP B STREPTOCOCCUS VACCINE.
*- Group B Streptococcus vaccine program licensed to Novartis - Intellectual property cross license agreement will allow Novartis to focus on vaccines and Intercell on therapeutic antibodies in this . . .

TECHNIQUE FOR CREATING RAT EMBRIONIC STEM CELLS PUBLISHED.
Stem Cell Sciences plc (AIM:STEM, ASX:STC) is pleased to announce that pioneering research describing a technique for creating authentic embryonic stem (ES) cells from rats has been published in the . . .

EURAND'S SUPPLIER SUBMITS RESPONSE TO FDA ON EUR-1008.
Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, has announc . . .

GENERICS INCURSION CAUSE A CYTOTOXIC MARKET DECLINE.
Cytotoxic therapy, or chemotherapy as it is commonly known, has been the cornerstone of cancer treatment for many years and involves the use of drugs that are toxic to all cells including those that . . .

S*BIO ADVANCES JAK2 INHIBITOR SB1518 INTO PHASE 1/2 TRIAL.
S*BIO Pte Ltd, Singapore, has announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with c . . .

GOVERNMENT OF CANADA PROCURES IMVAMUNE SMALLPOX VACCINE.
Following a Request for Proposal issued in 2007 with the intent to procure an MVA-based, third generation smallpox vaccine, Public Works and Government Services Canada, on behalf of the Canadian Dep . . .

DANISH BIOTECH PIPELINE RANKS THIRD IN EUROPE.
A strong pipeline makes the Copenhagen Region biotech cluster well prepared for the challenges ahead. With 185 drug candidates in preclinical and clinical development, Denmark ranks third in Europe. . . .

GENEREX BIOTECHNOLOGY AWARDED NEW DRUG DELIVERY PATENT.
Generex Biotechnology Corporation (Nasdaq:GNBT), Worcester, Mass., a leader in drug delivery for metabolic diseases through the inner lining of the mouth, has received a new patent in Australia. T . . .

QRXPHARMA/UNIV. OF ALABAMA COLLABORATE FOR PARKINSON'S RESEARCH.
QRxPharma Limited (ASX:QRX and OTCQX:QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system disor . . .

EXIQON REPORTS POSITIVE CLINICAL DATA FROM EORTC TRIAL.(Clinical report)
The European Organization for Research and Treatment of Cancer (EORTC) has undertaken a multi-institutional prospective randomized clinical trial on 719 late stage epithelial ovarian cancer patients . . .

INNEXUS BIOTECHNOLOGY GETS PATENT GRANTS IN EUROPE.
InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com/), British Columbia, Canada, a drug development company commercializing the next generation of monoclo . . .

FDA APPROVES CEPHALON TREANDA TO TREAT NON-HODGKINS LYMPHOMA.
Cephalon, Inc., (Nasdaq: CEPH) has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA(r) (bendamustine hydrochloride) for Injection for the treatment of patients with in . . .

ROCHE COMPLETES ACQUISITON OF ARIUS RESEARCH.
Roche, Basel. Switzerland, has completed the acquisition of 100% of the issued and outstanding shares and warrants of ARIUS Research (TSX: ARI). On September 19th, the Ontario Superior Court, Canada . . .

FDA ACCEPTS DATA FROM BRIDGE'S BEIJING FACILITY.
Bridge Laboratories, Gaithersburg, Md., has announced that the FDA has accepted data submitted from its Beijing facility on behalf of a US biotech client. The Good Laboratory Practices (GLP) nonhuma . . .

DEBIOPHARM/EPFL TO IDENTIFY INHIBITORS FOR CANCER TREATMENT.
Debiopharm Group (Debiopharm), Lausanne, Switzerland, a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, has announced th . . .

AVANTOGEN'S HAWAII BIOTECH GETS WALTER REED TRIAL SUPPORT.
Avantogen Ltd (ASX: ACU) has announced additional support for the Dengue vaccine program developed by Hawaii Biotech Inc, in which Avantogen holds a significant investment stake. The Dengue clinic . . .

IS COST CONTAINMENT IMPACTING PHARMACEUTICAL INNOVATION?
With the costs of providing healthcare spiraling, governments and payers across the seven major markets are implementing cost-cutting initiatives in an effort to combat these escalating healthcare c . . .

CYTOPIA BEGINS SECOND PHASE II STUDY IN BRAIN CANCER.
Cytopia Limited, Melbourne, Australia, is commencing enrolment for its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, in patients with an aggressive form of b . . .

EDEN BIODESIGN/HUMAN GENOME SCIENCES SIGN PACT.(Company overview)
Eden Biodesign Ltd., an expert provider of biopharmaceutical process development and cGMP manufacturing services, has entered into a marketing services agreement with Human Genome Sciences, Inc. (NA . . .

OREXO/PROSTRAKAN EXTEND LICENSING PACT FOR RAPINYL (ABSTRAL).
Orexo AB (OMX: ORX), the Swedish pharmaceutical company, and ProStrakan Group plc, the Scottish-based international specialty pharmaceutical company, have extended their existing European licensing . . .

GPC BIOTECH MARKETING AUTHORIZATION APPLICATION WITHDRAWN.
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) reported that the company has been informed by its partner for satraplatin in Europe that they plan to withdraw the Marketing Authorizati . . .

CYTOPIA APPOINTS STUDY CHAIRMAN FOR JAK2 CLINICAL TRIAL.
Cytopia Limited (ASX:CYT) has appointed Dr Ayalew Tefferi, Professor of Medicine and Hematology at the Mayo Clinic College of Medicine, as Clinical Study Chair for the company's Phase I/II study in . . .

YAMAGATA FUJITSU ORDERS IMPRIO HD2200 NANOPATTERNING SYSTEM.
Molecular Imprints, Inc., Austin, Texas, the market and technology leader for nanopatterning systems and solutions, has announced that Yamagata Fujitsu has placed an order for its newly introduced I . . .

SUBJECTS ENROLLED IN PRESEPT COLORECTAL CANCER SCREENING.
Epigenomics AG (Frankfurt:ECX), a molecular diagnostics company focusing on the development and commercialization of products for cancer detection based on DNA methylation, has announced the enrollm . . .